-
Product Insights
Net Present Value Model: AR-15512
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model AR-15512 Drug Details AR-15512 is under...
-
Track & Monitor
Immuno-oncology in Pharmaceuticals: Quinoline derivatives as anticancer agents
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – dexamethasone XR
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry dexamethasone XR Drug Details Dexamethasone is under development for the treatment of wet age...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AR-15512
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AR-15512 Drug Details AR-15512 is under development for the treatment of dry eye syndrome....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AR-13503 SR
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AR-13503 SR Drug Details AR-13503 is under development for the treatment of wet age-related...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – netarsudil mesylate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry netarsudil mesylate Drug Details Netarsudil mesylate (Rhopressa, Rhokiinsa) acts as an Antiglaucomas agent. It...
-
Product Insights
Keratoconjunctivitis sicca (Dry Eye) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues, and immunosuppressants. The KCS pipeline drugs market research report provides an analysis of the KCS drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The...
-
Product Insights
Glaucoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glaucoma signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision, and reddening of the eye. The Glaucoma pipeline drugs market research report provides an analysis of the Glaucoma drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and...
-
Product Insights
Uveitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Uveitis symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye, and sensitivity to light. Treatment includes steroid eye drops, anti-inflammatory, and antibiotic or antiviral medication. The Uveitis pipeline drugs market research report provides an analysis of the Uveitis drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history,...